Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1118

1.

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.

Gökbuget N, Dombret H, Giebel S, Bruggemann M, Doubek M, Foà R, Hoelzer D, Kim C, Martinelli G, Parovichnikova E, Rambaldi A, Ribera JM, Schoonen M, Stieglmaier JM, Zugmaier G, Bassan R.

Hematology. 2019 Dec;24(1):337-348. doi: 10.1080/16078454.2019.1567654.

PMID:
30757960
2.

Operative outcome of patients at low, intermediate, high and 'very high' surgical risk undergoing isolated aortic valve replacement with sutureless and rapid deployment prostheses: results of the SURD-IR registry.

Santarpino G, Berretta P, Fischlein T, Carrel TP, Teoh K, Misfeld M, Savini C, Kappert U, Glauber M, Villa E, Meuris B, Mignosa C, Albertini A, Martinelli G, Folliguet TA, Shrestha M, Solinas M, Laufer G, Phan K, Yan T, Di Eusanio M.

Eur J Cardiothorac Surg. 2019 Jan 25. doi: 10.1093/ejcts/ezy477. [Epub ahead of print]

PMID:
30689828
3.

Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers.

Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T.

Dis Markers. 2018 Dec 2;2018:6878409. doi: 10.1155/2018/6878409. eCollection 2018.

4.

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, Gökbuget N, Martinelli G, O'Brien S, White JL, Wang T, Luisa Paccagnella M, Sleight B, Vandendries E, DeAngelo DJ, Kantarjian HM.

Am J Hematol. 2019 Jan 8. doi: 10.1002/ajh.25394. [Epub ahead of print]

PMID:
30623490
5.

Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.

Simonetti G, Padella A, do Valle IF, Fontana MC, Fonzi E, Bruno S, Baldazzi C, Guadagnuolo V, Manfrini M, Ferrari A, Paolini S, Papayannidis C, Marconi G, Franchini E, Zuffa E, Laginestra MA, Zanotti F, Astolfi A, Iacobucci I, Bernardi S, Sazzini M, Ficarra E, Hernandez JM, Vandenberghe P, Cools J, Bullinger L, Ottaviani E, Testoni N, Cavo M, Haferlach T, Castellani G, Remondini D, Martinelli G.

Cancer. 2019 Mar 1;125(5):712-725. doi: 10.1002/cncr.31837. Epub 2018 Nov 27.

PMID:
30480765
6.

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.

Bertamini L, Nanni J, Marconi G, Abbenante M, Robustelli V, Bacci F, Matti A, Paolini S, Sartor C, Monaco SL, Fontana MC, De Polo S, Cavo M, Curti A, Martinelli G, Papayannidis C.

BMC Cancer. 2018 Nov 15;18(1):1117. doi: 10.1186/s12885-018-5026-x.

7.

Novel Agents for Acute Myeloid Leukemia.

Luppi M, Fabbiano F, Visani G, Martinelli G, Venditti A.

Cancers (Basel). 2018 Nov 9;10(11). pii: E429. doi: 10.3390/cancers10110429. Review.

8.

Network integration of multi-tumour omics data suggests novel targeting strategies.

do Valle ÍF, Menichetti G, Simonetti G, Bruno S, Zironi I, Durso DF, Mombach JCM, Martinelli G, Castellani G, Remondini D.

Nat Commun. 2018 Oct 30;9(1):4514. doi: 10.1038/s41467-018-06992-7.

9.

Leukemia cutis in a Ph+ ALL patient treated with ponatinib.

Pileri A, Papayannidis C, Messori S, Bacci F, Sagramoso CA, Martinelli G, Patrizi A.

G Ital Dermatol Venereol. 2018 Oct;153(5):730-731. doi: 10.23736/S0392-0488.17.05647-4. No abstract available.

PMID:
30246954
10.

Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study.

Bonifazi F, Dan E, Labopin M, Sessa M, Guadagnuolo V, Ferioli M, Rizzi S, De Carolis S, Sinigaglia B, Motta MR, Bontadini A, Giudice V, Martinelli G, Arpinati M, Cavo M, Bonafé M, Storci G.

Bone Marrow Transplant. 2018 Sep 19. doi: 10.1038/s41409-018-0335-x. [Epub ahead of print]

PMID:
30232415
11.

Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.

Ghelli Luserna Di Rorà A, Beeharry N, Imbrogno E, Ferrari A, Robustelli V, Righi S, Sabattini E, Verga Falzacappa MV, Ronchini C, Testoni N, Baldazzi C, Papayannidis C, Abbenante MC, Marconi G, Paolini S, Parisi S, Sartor C, Fontana MC, De Matteis S, Iacobucci I, Pelicci PG, Cavo M, Yen TJ, Martinelli G.

J Hematol Oncol. 2018 Aug 1;11(1):99. doi: 10.1186/s13045-018-0641-1.

12.

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.

Berdeja J, Palandri F, Baer MR, Quick D, Kiladjian JJ, Martinelli G, Verma A, Hamid O, Walgren R, Pitou C, Li PL, Gerds AT.

Leuk Res. 2018 Aug;71:82-88. doi: 10.1016/j.leukres.2018.06.014. Epub 2018 Jun 30.

PMID:
30025280
13.

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.

Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R.

Br J Haematol. 2018 Oct;183(1):35-46. doi: 10.1111/bjh.15497. Epub 2018 Jul 16.

PMID:
30010187
14.

Main changes in European Clinical Trials Regulation (No 536/2014).

Tenti E, Simonetti G, Bochicchio MT, Martinelli G.

Contemp Clin Trials Commun. 2018 May 17;11:99-101. doi: 10.1016/j.conctc.2018.05.014. eCollection 2018 Sep.

15.

Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.

L'Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D'Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2018 Oct;32(10):2304. doi: 10.1038/s41375-018-0177-y.

PMID:
29985446
16.

Aneuploidy: Cancer strength or vulnerability?

Simonetti G, Bruno S, Padella A, Tenti E, Martinelli G.

Int J Cancer. 2019 Jan 1;144(1):8-25. doi: 10.1002/ijc.31718. Epub 2018 Oct 31. Review.

PMID:
29981145
17.

Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Spagnoli A, Voso MT, Fianchi L, Papayannidis C, Gaidano GL, Breccia M, Musto P, De Bellis E, Del Principe MI, Lunghi M, Lessi F, Martinelli G, Venditti A.

Ann Hematol. 2018 Oct;97(10):1767-1774. doi: 10.1007/s00277-018-3374-x. Epub 2018 Jun 10.

PMID:
29947973
18.

Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients.

De Matteis S, Molinari C, Abbati G, Rossi T, Napolitano R, Ghetti M, Di Rorà AGL, Musuraca G, Lucchesi A, Rigolin GM, Cuneo A, Calistri D, Fattori PP, Bonafè M, Martinelli G.

J Transl Med. 2018 Jun 20;16(1):172. doi: 10.1186/s12967-018-1545-0.

19.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ.

Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.

20.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.

PMID:
29859851
21.

Group I Paks support muscle regeneration and counteract cancer-associated muscle atrophy.

Cerquone Perpetuini A, Re Cecconi AD, Chiappa M, Martinelli GB, Fuoco C, Desiderio G, Castagnoli L, Gargioli C, Piccirillo R, Cesareni G.

J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):727-746. doi: 10.1002/jcsm.12303. Epub 2018 May 21.

22.

Sutureless and Rapid-Deployment Aortic Valve Replacement International Registry (SURD-IR): early results from 3343 patients.

Di Eusanio M, Phan K, Berretta P, Carrel TP, Andreas M, Santarpino G, Di Bartolomeo R, Folliguet T, Meuris B, Mignosa C, Martinelli G, Misfeld M, Glauber M, Kappert U, Shrestha M, Albertini A, Teoh K, Villa E, Yan T, Solinas M.

Eur J Cardiothorac Surg. 2018 Oct 1;54(4):768-773. doi: 10.1093/ejcts/ezy132.

PMID:
29617925
23.

First Lattice Calculation of the QED Corrections to Leptonic Decay Rates.

Giusti D, Lubicz V, Tarantino C, Martinelli G, Sachrajda CT, Sanfilippo F, Simula S, Tantalo N.

Phys Rev Lett. 2018 Feb 16;120(7):072001. doi: 10.1103/PhysRevLett.120.072001.

PMID:
29542981
24.

Chromothripsis in acute myeloid leukemia: biological features and impact on survival.

Fontana MC, Marconi G, Feenstra JDM, Fonzi E, Papayannidis C, Ghelli Luserna di Rorá A, Padella A, Solli V, Franchini E, Ottaviani E, Ferrari A, Baldazzi C, Testoni N, Iacobucci I, Soverini S, Haferlach T, Guadagnuolo V, Semerad L, Doubek M, Steurer M, Racil Z, Paolini S, Manfrini M, Cavo M, Simonetti G, Kralovics R, Martinelli G.

Leukemia. 2018 Jul;32(7):1609-1620. doi: 10.1038/s41375-018-0035-y. Epub 2018 Feb 23.

25.

MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.

L Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2018 Oct;32(10):2152-2166. doi: 10.1038/s41375-018-0033-0. Epub 2018 Feb 22. Erratum in: Leukemia. 2018 Jul 9;:.

26.

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.

Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G.

Mol Cancer. 2018 Feb 19;17(1):49. doi: 10.1186/s12943-018-0780-6. Review.

27.

Assessment of the potential hazard represented by natural raw materials containing mineral fibres-The case of the feldspar from Orani, Sardinia (Italy).

Gualtieri AF, Gandolfi NB, Pollastri S, Rinaldi R, Sala O, Martinelli G, Bacci T, Paoli F, Viani A, Vigliaturo R.

J Hazard Mater. 2018 May 15;350:76-87. doi: 10.1016/j.jhazmat.2018.02.012. Epub 2018 Feb 7.

PMID:
29453122
28.

Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.

Candoni A, Papayannidis C, Martinelli G, Simeone E, Gottardi M, Iacobucci I, Gherlinzoni F, Visani G, Baccarani M, Fanin R.

Am J Hematol. 2018 May;93(5):655-663. doi: 10.1002/ajh.25057. Epub 2018 Mar 2.

PMID:
29396857
29.

Chromothripsis in acute myeloid leukemia: Biological features and impact on survival.

Fontana MC, Marconi G, Feenstra JDM, Fonzi E, Papayannidis C, di Rorá AGL, Padella A, Solli V, Franchini E, Ottaviani E, Ferrari A, Baldazzi C, Testoni N, Iacobucci I, Soverini S, Haferlach T, Guadagnuolo V, Semerad L, Doubek M, Steurer M, Racil Z, Paolini S, Manfrini M, Cavo M, Simonetti G, Kralovics R, Martinelli G.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.351. [Epub ahead of print]

30.

Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia.

De Dominici M, Porazzi P, Soliera AR, Mariani SA, Addya S, Fortina P, Peterson LF, Spinelli O, Rambaldi A, Martinelli G, Ferrari A, Iacobucci I, Calabretta B.

Cancer Res. 2018 Feb 15;78(4):1097-1109. doi: 10.1158/0008-5472.CAN-17-2644. Epub 2017 Dec 12.

31.

Blinatumomab in Ph+ B-ALL: present and perspectives.

Papayannidis C, Martinelli G.

Oncotarget. 2017 Oct 25;8(55):93309-93310. doi: 10.18632/oncotarget.22071. eCollection 2017 Nov 7. No abstract available.

32.

The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.

Sanarico AG, Ronchini C, Croce A, Memmi EM, Cammarata UA, De Antoni A, Lavorgna S, Divona M, Giacò L, Melloni GEM, Brendolan A, Simonetti G, Martinelli G, Mancuso P, Bertolini F, Coco FL, Melino G, Pelicci PG, Bernassola F.

Leukemia. 2018 Apr;32(4):911-919. doi: 10.1038/leu.2017.342. Epub 2017 Dec 6.

33.

MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences.

ĹAbbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2017 Nov 28. doi: 10.1038/leu.2017.337. [Epub ahead of print]

PMID:
29180669
34.

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia.

Mancini M, Soverini S, Gugliotta G, Santucci MA, Rosti G, Cavo M, Martinelli G, Castagnetti F.

Oncotarget. 2017 Sep 22;8(50):88244-88250. doi: 10.18632/oncotarget.21166. eCollection 2017 Oct 20. Review.

35.

Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor.

Cattina F, Bernardi S, Mantovani V, Toffoletti E, Santoro A, Pastore D, Martino B, Console G, Martinelli G, Malagola M.

Hematol Rep. 2017 Sep 26;9(3):7051. eCollection 2017 Sep 26. No abstract available.

36.

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia.

Gottardi M, Mosna F, de Angeli S, Papayannidis C, Candoni A, Clavio M, Tecchio C, Piccin A, dell'Orto MC, Benedetti F, Martinelli G, Gherlinzoni F.

Hematol Rep. 2017 Sep 26;9(3):7029. doi: 10.4081/hr.2017.7028. eCollection 2017 Sep 26. No abstract available.

37.

Mildly elevated lactate levels are associated with microcirculatory flow abnormalities and increased mortality: a microSOAP post hoc analysis.

Vellinga NAR, Boerma EC, Koopmans M, Donati A, Dubin A, Shapiro NI, Pearse RM, van der Voort PHJ, Dondorp AM, Bafi T, Fries M, Akarsu-Ayazoglu T, Pranskunas A, Hollenberg S, Balestra G, van Iterson M, Sadaka F, Minto G, Aypar U, Hurtado FJ, Martinelli G, Payen D, van Haren F, Holley A, Gomez H, Mehta RL, Rodriguez AH, Ruiz C, Canales HS, Duranteau J, Spronk PE, Jhanji S, Hubble S, Chierego M, Jung C, Martin D, Sorbara C, Bakker J, Ince C; microSOAP study group.

Crit Care. 2017 Oct 18;21(1):255. doi: 10.1186/s13054-017-1842-7.

38.

Feasibility and safety of early discharge after transfemoral transcatheter aortic valve implantation - rationale and design of the FAST-TAVI registry.

Barbanti M, Baan J, Spence MS, Iacovelli F, Martinelli GL, Saia F, Bortone AS, van der Kley F, Muir DF, Densem CG, Vis M, van Mourik MS, Seilerova L, Lüske CM, Bramlage P, Tamburino C.

BMC Cardiovasc Disord. 2017 Oct 10;17(1):259. doi: 10.1186/s12872-017-0693-0.

39.

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.

Younes A, Salles G, Martinelli G, Bociek RG, Barrigon DC, Barca EG, Turgut M, Gerecitano J, Kong O, Pisal CB, Tavorath R, Kim WS.

Haematologica. 2017 Dec;102(12):2104-2112. doi: 10.3324/haematol.2017.169656. Epub 2017 Sep 29.

40.

RALE051: a novel established cell line of sporadic Burkitt lymphoma.

L'Abbate A, Iacobucci I, Lonoce A, Turchiano A, Ficarra E, Paciello G, Cattina F, Ferrari A, Imbrogno E, Agostinelli C, Zinzani P, Martinelli G, Derenzini E, Storlazzi CT.

Leuk Lymphoma. 2018 May;59(5):1252-1255. doi: 10.1080/10428194.2017.1372580. Epub 2017 Sep 11. No abstract available.

PMID:
28893133
41.

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.

De Benedittis C, Papayannidis C, Venturi C, Abbenante MC, Paolini S, Parisi S, Sartor C, Cavo M, Martinelli G, Soverini S.

BMC Cancer. 2017 Aug 5;17(1):523. doi: 10.1186/s12885-017-3511-2.

42.

Distal Ulnar Artery Aneurysm Repair by End-to-End Technique: A Case Report.

Cotroneo A, Barillà D, Armienti F, Martinelli GL, Diena M.

Ann Vasc Surg. 2018 Jan;46:367.e15-367.e17. doi: 10.1016/j.avsg.2017.07.025. Epub 2017 Jul 21.

PMID:
28739457
43.

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.

Martinelli G, Mancini M, De Benedittis C, Rondoni M, Papayannidis C, Manfrini M, Meggendorfer M, Calogero R, Guadagnuolo V, Fontana MC, Bavaro L, Padella A, Zago E, Pagano L, Zanotti R, Scaffidi L, Specchia G, Albano F, Merante S, Elena C, Savini P, Gangemi D, Tosi P, Ciceri F, Poletti G, Riccioni L, Morigi F, Delledonne M, Haferlach T, Cavo M, Valent P, Soverini S.

Leukemia. 2018 Jan;32(1):139-148. doi: 10.1038/leu.2017.183. Epub 2017 Jun 16.

44.

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M.

Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jul;19(7):e335.

45.

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Albano F, Iurlo A, Intermesoli T, Abruzzese E, Levato L, D'Adda M, Pregno P, Cavazzini F, Stagno F, Martino B, La Barba G, Sorà F, Tiribelli M, Bigazzi C, Binotto G, Bonifacio M, Caracciolo C, Soverini S, Foà R, Cavo M, Martinelli G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell’Adulto - Chronic Myeloid Leukemia Working Party.

Haematologica. 2017 Sep;102(9):1530-1536. doi: 10.3324/haematol.2017.169532. Epub 2017 Jun 1.

46.

Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.

Latagliata R, Polverelli N, Tieghi A, Palumbo GA, Breccia M, Sabattini E, Villari L, Riminucci M, Valli R, Catani L, Alimena G, Ottaviani E, Fama A, Martinelli G, Perricone M, Spinsanti M, Cavo M, Vianelli N, Palandri F.

Hematol Oncol. 2018 Feb;36(1):269-275. doi: 10.1002/hon.2430. Epub 2017 May 16.

PMID:
28509339
47.

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Perricone M, Palandri F, Ottaviani E, Angelini M, Bagli L, Bellesia E, Donati M, Gemmati D, Zucchini P, Mancini S, Marchica V, Trubini S, De Matteis G, Di Zacomo S, Favarato M, Fioroni A, Bolzonella C, Maccari G, Navaglia F, Gatti D, Toffolatti L, Orlandi L, Laloux V, Manfrini M, Galieni P, Giannini B, Tieghi A, Barulli S, Serino ML, Maccaferri M, Scortechini AR, Giuliani N, Vallisa D, Bonifacio M, Accorsi P, Salbe C, Fazio V, Gusella M, Toffoletti E, Salvucci M, Svaldi M, Gherlinzoni F, Cassavia F, Orsini F, Martinelli G.

Oncotarget. 2017 May 16;8(20):32608-32617. doi: 10.18632/oncotarget.15940.

48.

The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.

Perricone M, Polverelli N, Martinelli G, Catani L, Ottaviani E, Zuffa E, Franchini E, Dizdari A, Forte D, Sabattini E, Cavo M, Vianelli N, Palandri F.

Oncotarget. 2017 Jun 6;8(23):37239-37249. doi: 10.18632/oncotarget.16744.

49.

Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells.

Daniele G, Simonetti G, Fusilli C, Iacobucci I, Lonoce A, Palazzo A, Lomiento M, Mammoli F, Marsano RM, Marasco E, Mantovani V, Quentmeier H, Drexler HG, Ding J, Palumbo O, Carella M, Nadarajah N, Perricone M, Ottaviani E, Baldazzi C, Testoni N, Papayannidis C, Ferrari S, Mazza T, Martinelli G, Storlazzi CT.

Haematologica. 2017 Jul;102(7):1204-1214. doi: 10.3324/haematol.2016.163022. Epub 2017 Apr 14.

50.

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.

Luatti S, Baldazzi C, Marzocchi G, Ameli G, Bochicchio MT, Soverini S, Castagnetti F, Tiribelli M, Gugliotta G, Martinelli G, Baccarani M, Cavo M, Rosti G, Testoni N.

Oncotarget. 2017 May 2;8(18):29906-29913. doi: 10.18632/oncotarget.15369.

Supplemental Content

Loading ...
Support Center